Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients (Q33586790)

28 July 2017

1 reference

title

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients (English)

1 reference

28 July 2017

1 reference

1 reference

1 reference

1 reference

Locarnini S

1 reference

28 July 2017

Birch C

series ordinal

1 reference

28 July 2017

publication date

1 March 1999

1 reference

28 July 2017

published in

Journal of Hepatology

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

536-550

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

28 July 2017

1 reference

7 January 2021

Review: Present and future directions in the treatment of chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Changing the natural history of HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

The accuracy of reverse transcriptase from HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Survival in chronic hepatitis B. An analysis of 379 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Influence of T‐helper cell subsets and crossregulation in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Treatment of chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Effect of interferon on hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

RNA virus populations as quasispecies.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Viral dynamics of HIV: implications for drug development and therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Clinical experience with famciclovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

A Single-Dose Study to Assess the Penetration of Stavudine Into Human Cerebrospinal Fluid in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Absorption and Elimination Kinetics of Zidovudine in the Cerebrospinal Fluid in HIV-1-Infected Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

The entry of antiviral and antiretroviral drugs into the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Significance of extrahepatic replication of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Chronic hepatitis B: the therapeutic challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Therapy for human immunodeficiency virus infection -- what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Viral counts count in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Statistical models for predicting a beneficial response to interferon-alpha in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Mitochondrial toxicity of antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Time to hit HIV, early and hard.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Combination therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980118-4

7 January 2021

10.1016/S0168-8278(99)80118-4

Identifiers

DOI

1 reference

release_hvh6uyznrfdp5kwzo5pw54qr7i

28 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hvh6uyznrfdp5kwzo5pw54qr7i

24 November 2022

mapped directly with Wikidata item

1 reference